Share on StockTwits

Equities research analysts at JMP Securities started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued to investors on Tuesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock.

A number of other firms have also recently commented on MRNS. Analysts at Stifel Nicolaus initiated coverage on shares of Marinus Pharmaceuticals in a research note on Monday. They set a “buy” rating and a $11.00 price target on the stock. Analysts at Janney Montgomery Scott initiated coverage on shares of Marinus Pharmaceuticals in a research note on Monday. They set a “buy” rating and a $13.00 price target on the stock.

Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) opened at 8.04 on Tuesday. Marinus Pharmaceuticals has a one year low of $8.00 and a one year high of $8.16. The stock has a 50-day moving average of $8.02 and a 200-day moving average of $8.02. The company’s market cap is $4.0 million.

Marinus Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. The Company is focused on developing and commercializing neuropsychiatric therapeutics.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.